Shares of CVS Health Corporation (NYSE:CVS) saw unusually-strong trading volume on Monday . Approximately 5,475,254 shares were traded during trading, an increase of 26% from the previous session’s volume of 4,351,656 shares.The stock last traded at $93.91 and had previously closed at $96.55.

A number of brokerages have weighed in on CVS. Vetr upgraded shares of CVS Health Corporation from a “hold” rating to a “buy” rating and set a $113.29 target price for the company in a research report on Monday, April 4th. Morgan Stanley reiterated a “buy” rating on shares of CVS Health Corporation in a research report on Thursday, April 7th. Zacks Investment Research lowered shares of CVS Health Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, April 12th. Mizuho reiterated a “buy” rating and set a $117.00 target price (up previously from $104.00) on shares of CVS Health Corporation in a research report on Wednesday, May 4th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $115.00 target price (up previously from $110.00) on shares of CVS Health Corporation in a research report on Wednesday, May 4th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $112.98.

The firm’s 50 day moving average is $95.72 and its 200-day moving average is $98.31. The company has a market cap of $101.00 billion and a price-to-earnings ratio of 20.44.

CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings results on Tuesday, May 3rd. The pharmacy operator reported $1.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.02. The company had revenue of $43.20 billion for the quarter, compared to analysts’ expectations of $43.01 billion. CVS Health Corporation’s revenue for the quarter was up 18.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.14 EPS. On average, equities analysts expect that CVS Health Corporation will post $5.82 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Thursday, July 21st will be issued a dividend of $0.425 per share. The ex-dividend date is Tuesday, July 19th. This represents a $1.70 annualized dividend and a yield of 1.81%.

In other news, CEO Larry J. Merlo sold 38,247 shares of the company’s stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $105.00, for a total transaction of $4,015,935.00. Following the completion of the transaction, the chief executive officer now directly owns 280,381 shares of the company’s stock, valued at approximately $29,440,005. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Troyen A. Brennan sold 7,517 shares of the company’s stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $105.00, for a total value of $789,285.00. Following the transaction, the executive vice president now directly owns 69,601 shares of the company’s stock, valued at $7,308,105. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have added to or reduced their stakes in CVS. Brown Advisory Securities LLC boosted its position in CVS Health Corporation by 14.8% in the fourth quarter. Brown Advisory Securities LLC now owns 10,306 shares of the pharmacy operator’s stock valued at $1,006,000 after buying an additional 1,331 shares in the last quarter. Sawtooth Asset Management Inc. boosted its position in CVS Health Corporation by 96.0% in the fourth quarter. Sawtooth Asset Management Inc. now owns 10,624 shares of the pharmacy operator’s stock valued at $1,039,000 after buying an additional 5,203 shares in the last quarter. Checchi Capital Advisers LLC boosted its position in CVS Health Corporation by 9.0% in the fourth quarter. Checchi Capital Advisers LLC now owns 10,701 shares of the pharmacy operator’s stock valued at $1,046,000 after buying an additional 882 shares in the last quarter. WMS Partners LLC boosted its position in CVS Health Corporation by 1.4% in the fourth quarter. WMS Partners LLC now owns 11,098 shares of the pharmacy operator’s stock valued at $1,085,000 after buying an additional 158 shares in the last quarter. Finally, Usca Ria LLC boosted its position in CVS Health Corporation by 14.9% in the fourth quarter. Usca Ria LLC now owns 11,137 shares of the pharmacy operator’s stock valued at $1,089,000 after buying an additional 1,442 shares in the last quarter.

CVS Health Corporation, together with its subsidiaries, is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit management (PBM) services and operates under the CVS/caremark Pharmacy Services, Novologix and Navarro Health Services names.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.